BRACO 19 trihydrochloride

Category	Cytomegalovirus (CMV)
CAS	1177798-88-7
Description	BRACO 19 trihydrochloride is a telomerase inhibitor (IC50 = 115 nM) that suppresses the expression of human telomerase reverse transcriptase (hTERT) and induces cellular senescence. BRACO 19 was shown to inhibit growth of uterine cancer cells in vitro and growth of uterine tumor xenografts in mice.

Quotation Now

Product Information

Synonyms	N,N'-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide trihydrochloride
Molecular Weight	703.14
Molecular Formula	C35H43N7O2.3HCl
Canonical SMILES	CN(C)C1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=C2C=CC(=C4)NC(=O)CCN5CCCC5)NC(=O)CCN6CCCC6.Cl.Cl.Cl
InChI	InChI=1S/C35H43N7O2.3ClH/c1-40(2)28-11-7-25(8-12-28)38-35-29-13-9-26(36-33(43)15-21-41-17-3-4-18-41)23-31(29)39-32-24-27(10-14-30(32)35)37-34(44)16-22-42-19-5-6-20-42;;;/h7-14,23-24H,3-6,15-22H2,1-2H3,(H,36,43)(H,37,44)(H,38,39);3*1H
InChIKey	MJAPNWJRLLDPAB-UHFFFAOYSA-N
Purity	≥95% by HPLC
Solubility	In Vitro: H2O : 22 mg/mL(31.29 mM;Need ultrasonic and warming)
Appearance	Brown to black (Solid)
Storage	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture)
Complexity	870
Exact Mass	701.277857
In Vitro	Braco-19 trihydrochloride, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication. BRACO-19 trihydrochloride (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC100 is 5 μM. BRACO-19 trihydrochloride (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses. BRACO-19 trihydrochloride (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells. BRACO-19 trihydrochloride (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner.
In Vivo	Braco-19 trihydrochloride showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.
Target	DNA/RNA Synthesis; CMV